Search
01/01/2023
Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)
Navarro-Compán V., Puig L., Vidal S., Ramírez J., Llamas-Velasco M., Fernández-Carballido C., Almodóvar R., Pinto J.A., Galíndez-Aguirregoikoa E., Zarco P., Joven B., Gratacós J., Juanola X., Blanco R., Arias-Santiago S., Sanz J.S., Queiro R., Cañete J.D.. Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782). Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1332177. PMID:. IF:(Q/D).
30/12/2022
The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.
Furlano M, Ars E, Matamala A, Brossa V, Martí J, Del Prado-Venegas M, Crespi J, Roe E, Torra R. The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.. Case Reports In Genetics. 2022; 2022DOI:10.1155/2022/3208810. PMID:36619006. IF:(Q/D).
01/06/2025
Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study
Augustin, M, Serra-Baldrich, E, Seneschal, J, Grond, S, Lampropoulou, A, Elrayes, M, Ogwu, S, de la Torre, I, Bewley, A, Pinter, A. Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study. ADVANCES IN THERAPY. 2025; 42(6)DOI:10.1007/s12325-025-03137-3. PMID:40192965. IF:4.000(Q1/3D).
01/06/2025
Cholinergic Pruritus as an Early Sign of Essential Thrombocythemia With Therapeutic Response to Ruxolitinib
Mateu-Arrom, L, Serra-Baldrich, E, Puig, L. Cholinergic Pruritus as an Early Sign of Essential Thrombocythemia With Therapeutic Response to Ruxolitinib. Actas Dermo-Sifiliograficas. 2025; 116(6)DOI:10.1016/j.ad.2023.09.035. PMID:39947585. IF:(Q/D).